The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.f

Hypoxemia, low oxygen saturation (may occur in isolation)

Publications

Yoshida I, Matsuo K, Teshima T, Hashimoto D, Tanimoto Y, Harada M, Tanimoto M

Transient respiratory disturbance by granulocyte-colony-stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation.

Transfusion 2006 Feb;46;186-92 — 2006 Feb — 186-92

Khoury H, Adkins D, Brown R, Vij R, Westervelt P, Trinkaus K, Goodnough LT, DiPersio JF

Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation.

Bone marrow transplantation 2000 Jun;25;1197-201 — 2000 Jun — 1197-201

Bukowski RM, Murthy S, McLain D, Finke J, Andresen S, Tubbs R, Bauer L, Gibson V, Budd GT, Thomassen MJ

Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effects.

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993 May 04;13;267-74 — 1993 May 04 — 267-74

Schilero GJ, Oropello J, Benjamin E

Impairment in gas exchange after granulocyte colony stimulating factor (G-CSF) in a patient with the adult respiratory distress syndrome.

Chest 1995 Jan;107;276-8 — 1995 Jan — 276-8

Lieschke GJ, Cebon J, Morstyn G

Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor.

Blood 1989 Dec;74;2634-43 — 1989 Dec — 2634-43